Neoadjuvant Chemo-immunotherapy for Stage III PD-L1 Positive Non-Small Cell Lung Cancer (NSCLC)

NCT07264647 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

30

Enrollment

OTHER

Sponsor class

Conditions

Stage III NSCLC

Interventions

DRUG: Tislelizumab
PROCEDURE: surgery (any volume) and / or pharmaceuticals treatment initiated or planned or only dynamic observation, in accordance with current clinical guidelines
RADIATION: Chemoradiotherapy

Sponsor

Fondazione Ricerca Traslazionale